Cargando…

[(18)F]Atorvastatin Pharmacokinetics and Biodistribution in Healthy Female and Male Rats

[Image: see text] Statins are 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors that are widely used to prevent cardiovascular diseases. However, a series of pleiotropic mechanisms have been associated with statins, particularly with atorvastatin. Therefore, the assessment of [(18)F]atorvas...

Descripción completa

Detalles Bibliográficos
Autores principales: Clemente, Gonçalo S., Antunes, Inês F., Sijbesma, Jürgen W. A., van Waarde, Aren, Lammertsma, Adriaan A., Dömling, Alexander, Elsinga, Philip H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2021
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8424645/
https://www.ncbi.nlm.nih.gov/pubmed/34351158
http://dx.doi.org/10.1021/acs.molpharmaceut.1c00305
_version_ 1783749704468660224
author Clemente, Gonçalo S.
Antunes, Inês F.
Sijbesma, Jürgen W. A.
van Waarde, Aren
Lammertsma, Adriaan A.
Dömling, Alexander
Elsinga, Philip H.
author_facet Clemente, Gonçalo S.
Antunes, Inês F.
Sijbesma, Jürgen W. A.
van Waarde, Aren
Lammertsma, Adriaan A.
Dömling, Alexander
Elsinga, Philip H.
author_sort Clemente, Gonçalo S.
collection PubMed
description [Image: see text] Statins are 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors that are widely used to prevent cardiovascular diseases. However, a series of pleiotropic mechanisms have been associated with statins, particularly with atorvastatin. Therefore, the assessment of [(18)F]atorvastatin kinetics with positron emission tomography (PET) may elucidate the mechanism of action of statins and the impact of sexual dimorphism, which is one of the most debated interindividual variations influencing the therapeutic efficacy. [(18)F]Atorvastatin was synthesized via a previously optimized (18)F-deoxyfluorination strategy, used for preclinical PET studies in female and male Wistar rats (n = 7 for both groups), and for subsequent ex vivo biodistribution assessment. PET data were fitted to several pharmacokinetic models, which allowed for estimating relevant kinetic parameters. Both PET imaging and biodistribution studies showed negligible uptake of [(18)F]atorvastatin in all tissues compared with the primary target organ (liver), excretory pathways (kidneys and small intestine), and stomach. Uptake of [(18)F]atorvastatin was 38 ± 3% higher in the female liver than in the male liver. The irreversible 2-tissue compartment model showed the best fit to describe [(18)F]atorvastatin kinetics in the liver. A strong correlation (R(2) > 0.93) between quantitative K(i) (the radiotracer’s unidirectional net rate of influx between compartments) and semi-quantitative liver’s SUV (standard uptake value), measured between 40 to 90 min, showed potential to use the latter parameter, which circumvents the need for blood sampling as a surrogate of K(i) for monitoring [(18)F]atorvastatin uptake. Preclinical assays showed faster uptake and clearance for female rats compared to males, seemingly related to a higher efficiency for exchanges between the arterial input and the hepatic tissue. Due to the slow [(18)F]atorvastatin kinetics, equilibrium between the liver and plasma concentration was not reached during the time frame studied, making it difficult to obtain sufficient and accurate kinetic information to quantitatively characterize the radiotracer pharmacokinetics over time. Nevertheless, the reported results suggest that the SUV can potentially be used as a simplified measure, provided all scans are performed at the same time point. Preclinical PET-studies with [(18)F]atorvastatin showed faster uptake and clearance in female compared to male rats, apparently related to higher efficiency for exchange between arterial blood and hepatic tissue.
format Online
Article
Text
id pubmed-8424645
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-84246452021-09-08 [(18)F]Atorvastatin Pharmacokinetics and Biodistribution in Healthy Female and Male Rats Clemente, Gonçalo S. Antunes, Inês F. Sijbesma, Jürgen W. A. van Waarde, Aren Lammertsma, Adriaan A. Dömling, Alexander Elsinga, Philip H. Mol Pharm [Image: see text] Statins are 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors that are widely used to prevent cardiovascular diseases. However, a series of pleiotropic mechanisms have been associated with statins, particularly with atorvastatin. Therefore, the assessment of [(18)F]atorvastatin kinetics with positron emission tomography (PET) may elucidate the mechanism of action of statins and the impact of sexual dimorphism, which is one of the most debated interindividual variations influencing the therapeutic efficacy. [(18)F]Atorvastatin was synthesized via a previously optimized (18)F-deoxyfluorination strategy, used for preclinical PET studies in female and male Wistar rats (n = 7 for both groups), and for subsequent ex vivo biodistribution assessment. PET data were fitted to several pharmacokinetic models, which allowed for estimating relevant kinetic parameters. Both PET imaging and biodistribution studies showed negligible uptake of [(18)F]atorvastatin in all tissues compared with the primary target organ (liver), excretory pathways (kidneys and small intestine), and stomach. Uptake of [(18)F]atorvastatin was 38 ± 3% higher in the female liver than in the male liver. The irreversible 2-tissue compartment model showed the best fit to describe [(18)F]atorvastatin kinetics in the liver. A strong correlation (R(2) > 0.93) between quantitative K(i) (the radiotracer’s unidirectional net rate of influx between compartments) and semi-quantitative liver’s SUV (standard uptake value), measured between 40 to 90 min, showed potential to use the latter parameter, which circumvents the need for blood sampling as a surrogate of K(i) for monitoring [(18)F]atorvastatin uptake. Preclinical assays showed faster uptake and clearance for female rats compared to males, seemingly related to a higher efficiency for exchanges between the arterial input and the hepatic tissue. Due to the slow [(18)F]atorvastatin kinetics, equilibrium between the liver and plasma concentration was not reached during the time frame studied, making it difficult to obtain sufficient and accurate kinetic information to quantitatively characterize the radiotracer pharmacokinetics over time. Nevertheless, the reported results suggest that the SUV can potentially be used as a simplified measure, provided all scans are performed at the same time point. Preclinical PET-studies with [(18)F]atorvastatin showed faster uptake and clearance in female compared to male rats, apparently related to higher efficiency for exchange between arterial blood and hepatic tissue. American Chemical Society 2021-08-05 2021-09-06 /pmc/articles/PMC8424645/ /pubmed/34351158 http://dx.doi.org/10.1021/acs.molpharmaceut.1c00305 Text en © 2021 The Authors. Published by American Chemical Society https://creativecommons.org/licenses/by-nc-nd/4.0/Permits non-commercial access and re-use, provided that author attribution and integrity are maintained; but does not permit creation of adaptations or other derivative works (https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Clemente, Gonçalo S.
Antunes, Inês F.
Sijbesma, Jürgen W. A.
van Waarde, Aren
Lammertsma, Adriaan A.
Dömling, Alexander
Elsinga, Philip H.
[(18)F]Atorvastatin Pharmacokinetics and Biodistribution in Healthy Female and Male Rats
title [(18)F]Atorvastatin Pharmacokinetics and Biodistribution in Healthy Female and Male Rats
title_full [(18)F]Atorvastatin Pharmacokinetics and Biodistribution in Healthy Female and Male Rats
title_fullStr [(18)F]Atorvastatin Pharmacokinetics and Biodistribution in Healthy Female and Male Rats
title_full_unstemmed [(18)F]Atorvastatin Pharmacokinetics and Biodistribution in Healthy Female and Male Rats
title_short [(18)F]Atorvastatin Pharmacokinetics and Biodistribution in Healthy Female and Male Rats
title_sort [(18)f]atorvastatin pharmacokinetics and biodistribution in healthy female and male rats
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8424645/
https://www.ncbi.nlm.nih.gov/pubmed/34351158
http://dx.doi.org/10.1021/acs.molpharmaceut.1c00305
work_keys_str_mv AT clementegoncalos 18fatorvastatinpharmacokineticsandbiodistributioninhealthyfemaleandmalerats
AT antunesinesf 18fatorvastatinpharmacokineticsandbiodistributioninhealthyfemaleandmalerats
AT sijbesmajurgenwa 18fatorvastatinpharmacokineticsandbiodistributioninhealthyfemaleandmalerats
AT vanwaardearen 18fatorvastatinpharmacokineticsandbiodistributioninhealthyfemaleandmalerats
AT lammertsmaadriaana 18fatorvastatinpharmacokineticsandbiodistributioninhealthyfemaleandmalerats
AT domlingalexander 18fatorvastatinpharmacokineticsandbiodistributioninhealthyfemaleandmalerats
AT elsingaphiliph 18fatorvastatinpharmacokineticsandbiodistributioninhealthyfemaleandmalerats